Results 221 to 230 of about 1,344,517 (267)
Some of the next articles are maybe not open access.

Biomarkers: to be or not to be

Annals of the Rheumatic Diseases, 2020
We read with great interest the article by van den Hoogen et al 1 describing galectin-9 (Gal-9) as a novel, easy-to-measure biomarker for the interferon (IFN) signature in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). We support the views expressed by the authors that IFN signature is an important biomarker in disease activity
Sule, Yavuz, Lars, Rönnblom
openaire   +2 more sources

Sepsis Biomarkers

2021
Biomarkers have been used in sepsis to assist with the diagnosis of disease as well as determining the severity of disease, that is, prognosis. These biomarkers are based on the presence of discrete molecules within the blood. Unfortunately, in 2020, a single biomarker does not have sufficient sensitivity and specificity to definitively rule in or rule
Yachana, Kataria, Daniel, Remick
openaire   +2 more sources

Biomarkers

2015
Biomarkers are key tools and can provide crucial information on the complex cascade of events and molecular mechanisms underlying traumatic brain injury (TBI) pathophysiology. Obtaining a profile of distinct classes of biomarkers reflecting core pathologic mechanisms could enable us to identify and characterize the initial injury and the secondary ...
MONDELLO, STEFANIA, Hayes, Ronald L.
openaire   +2 more sources

Biomarkers in pediatrics: Children as biomarker orphans

PROTEOMICS – Clinical Applications, 2010
AbstractBiomarkers have enormous potential to improve patient care by establishing tests of diagnosis, prognosis, and treatment effects. Successfully translating a biomarker from discovery to clinical application demands high‐quality discovery research and high‐quality clinical studies for biomarker validation; however, there are additional challenges ...
William J, Savage, Allen D, Everett
openaire   +2 more sources

From biomarker strategies to biomarker activities and back

Drug Discovery Today, 2010
The pharmaceutical industry must find ways to improve the unacceptably high attrition rate during drug development. Clearly, pharma has moved away from treat-and-see testing of new drugs in patients, with a strong current focus on generating translational biomarkers early in the research process to enable more predictive evaluation of drug action in ...
Gool, A.J. van   +2 more
openaire   +4 more sources

Biomarkers of Immunosuppression

Critical Care Clinics, 2020
It is now recognized that sepsis is not a uniformly proinflammatory state. There is a well-recognized counter anti-inflammatory response that occurs in many patients. The timing and magnitude of this response varies considerably and thus makes its identification and manipulation more difficult.
Abinav K, Misra   +2 more
openaire   +2 more sources

Biomarkers of Aging

The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 1988
Abstract This article presents a conceptual discussion of some aspects involved in biomarkers in aging. A biomarker of aging is a biological parameter of an organism that either alone or in some multivariate composite will, in the absence of disease, better predict functional capability at some late age than will chronological age.
openaire   +3 more sources

Biomarkers of Frailty

Molecular Aspects of Medicine
Several biomarkers have been proposed to identify frailty, a multisystemic age-related syndrome. However, the complex pathophysiology and the absence of a consensus on a comprehensive and universal definition make it challenging to pinpoint a singular biomarker or set of biomarkers that conclusively characterize frailty.
Mariam, El Assar   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy